Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort

Rheumatoid Arthritis

Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial

Ann Rheum Dis.

Kuijper TM, Luime JJ, de Jong PH, Gerards AH, van Zeben D, Tchetverikov I, de Sonnaville PB, van Krugten MV, Grillet BA, Hazes JM, Weel AE

doi: 10.1136/

Further Publications Rheumatology

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register

Ann Rheum Dis

Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Schäfer M, Zink A, Strangfeld A

doi: 10.1136/annrheumdis-2021-220651

Further Publications Rheumatology

Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study

Semin Arthritis Rheum

Dormuth CR, Fisher A, Hudson M, Austin PC, Ernst P, Bresee L, Chateau D, Tamim H, Paterson JM, Lafrance JP, Taylor-Gjevre RM, Platt RW, Canadian Network For Observational Drug Effect Studies Cnodes Investigators

doi: 10.1016/j.semarthrit.2021.08.002

Rheumatoid Arthritis

Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis.

Arthritis Rheumatol.

Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH

doi: 10.1002/art.40054.

Rheumatoid Arthritis

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors

Ann Rheum Dis.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ

doi: 10.1136/annrheumdis-

Rheumatoid Arthritis

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis

Ann Rheum Dis.

Sharma C, Whittle S, Haghighi PD, Burstein F, Sa'adon R, Keen HI

doi: 10.1136/annrheumdis-2020-217333.

Rheumatoid Arthritis

Association between Vitamin D deficiency and disease activity, disability and radiographic progression in early rheumatoid arthritis. The ESPOIR cohort

J Rheumatol.

Mouterde G, Gamon E, Rincheval N, Lukas C, Seror R, Berenbaum F, Dupuy AM, Daien C, Daurès JP, Combe B

doi: 10.3899/jrheum.190795.

Rheumatoid Arthritis

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis

Arthritis Res Ther

Verstappen M, Niemantsverdriet E, Matthijssen XME, le Cessie S, van der Helm-van Mil AHM

doi: 10.1186/s13075-020-02368-9

Rheumatoid Arthritis

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS

doi: 10.1016/

Related content

Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register

Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study

Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis

Association between Vitamin D deficiency and disease activity, disability and radiographic progression in early rheumatoid arthritis. The ESPOIR cohort

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial